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Abstract: Noncovalent interactions between complex carbohy-
drates and proteins drive many fundamental processes within
biological systems, including human immunity. In this report we
aimed to investigate the potential of mannose-containing glyco-
polymers to interact with human DC-SIGN and the ability of these
glycopolymers to inhibit the interactions between DC-SIGN and
the HIV envelope glycoprotein gp120. We used a library of
glycopolymers that are prepared via combination of copper-
mediated living radical polymerization and azide-alkyne [3+2]
Huisgen cycloaddition reaction. We demonstrate that a relatively
simple glycopolymer can effectively prevent the interactions
between a human dendritic cell associated lectin (DC-SIGN) and
the viral envelope glycoprotein gp120. This approach may give
rise to novel insights into the mechanisms of HIV infection and
provide potential new therapeutics.
Noncovalent interactions between complex carbohydrates and
proteins drive many fundamental processes within biological
systems, including human immunity.
1-4 DC-SIGN (dendritic cell
speciﬁc ICAM-3 grabbing nonintegrin) is a C-type lectin of
signiﬁcant medical interest that is expressed on the surface of
dendritic cells: highly specialized cells that govern immune
responses.
5-7 DC-SIGN recognizes oligosaccharide structures on
host glycoproteins and regulates immune functions such as cytokine
production and antigen presentation. Importantly, DC-SIGN also
binds to carbohydrates on the surfaces of lethal opportunistic
pathogens, notably HIV-1, enhancing their adhesion, infectivity,
and persistence in patients.
5,8 Solid-phase competition assays have
demonstrated monosaccharide mannose binding to DC-SIGN with
millimolar afﬁnity, and that afﬁnity for oligosaccharide ligands such
as Man9GlcNAc2 is greatly enhanced.
9 High-resolution structural
studies have shown that DC-SIGN binds preferentially to complex
mannose oligosaccharide structures and the primary carbohydrate-
binding site selectively accommodates the equatorial stereochem-
istry of the C3 and C4 hydroxyls found in the mannopyranosides.
10
Furthermore, it has been determined previously that DC-SIGN exists
at the cell surface as a tetramer of identical polypeptide subunits
and that the oligomerization of sugar-binding lectin domains within
these tetramers is fundamental to achieving the high afﬁnity required
for selective binding to densely clustered carbohydrate ligands.
9,11
An important example of such a ligand is the highly glycosylated
gp120 envelope glycoprotein of HIV-1. Considering these, DC-
SIGN is an attractive target for synthetic mannose-containing
glycoconjugates.
In recent years, the use of synthetic glycopolymers to interact with
lectins or for other biotechnological applications has gained interest.
12-15
The presentation of multiple carbohydrate moieties along a polymer
backbone often results in increased binding to the complementary lectin
compared to the individual sugars, due to the cluster glycoside
effect.
16-20 Calorimetry studies indicate that this is an entropy-driven
process, but questions remain over the exact mechanisms.
21 This
increase in avidity has been exploited for anti-adhesion therapies
whereby the glycopolymer competes for microbial binding to lectins
to prevent infection or induces an anti-microbial cellular response.
22,23
For example, we recently demonstrated that glycopolymer-protein
conjugates could interact with mammalian mannose-binding lectin with
high afﬁnity.
24 Considering this, synthetic glycopolymers with high
afﬁnity for DC-SIGN represent attractive materials that could offer
important anti-microbial adhesion properties and provide novel thera-
peutic strategies for HIV treatment.
25
In this report we aimed to investigate the potential of mannose-
containing glycopolymers to interact with human DC-SIGN and
the ability these glycopolymers to inhibit the interactions between
DC-SIGN and the HIV envelope glycoprotein gp120. We used a
highly efﬁcient post-polymerization modiﬁcation approach
26,27
based on the alkyne-azide cycloaddition reaction (“click reac-
tion”)
28 to create a library of glycopolymers.
29-32 This method
allows control over the density of the carbohydrate binding moiety
along the polymer chain, while ensuring that each polymer has
identical chain length and chain length distribution, which is not
possible to achieve by direct polymerization of glycosylated
monomers. The well-deﬁned clickable polymer backbone was
synthesized by copper-mediated living radical polymerization of
trimethylsilyl propargyl methacrylate
33 to give a polymer with a
number-average degree of polymerization of ca. 58. Following the
removal of the trimethylsilyl group, copper(I)-catalyzed click
reaction was used to synthesize ﬁve glycopolymer species contain-
ing varying densities of R-D-mannose and -D-galactose, Figure 1.
Multichannel surface plasmon resonance (MC-SPR) was used to
investigate the binding afﬁnity of this library of glycopolymers with
bacterially expressed soluble recombinant human DC-SIGN tetramers.
DC-SIGN was immobilized onto a SPR sensor chip, Figure 1a, and
the interactions between DC-SIGN and the glycopolymers were probed
as a function of glycopolymer concentration. Figure 2 shows repre-
sentative SPR sensorgrams of the 100% mannose glycopolymer, P1,
and HIV gp120 analytes ﬂowed over the immobilized DC-SIGN. This
recombinant form of the gp120 envelope glycoprotein of HIV-1 is a
biological DC-SIGN ligand known to carry substantial amounts of
N-linked high mannose oligosaccharides. The sensorgrams demonstrate
that both P1 and gp120 bind to the DC-SIGN with high (nanomolar)
afﬁnity, in a dose-dependent fashion. Furthermore, the presentation
of mannose in clustered polymeric form was essential for high-afﬁnity
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signal. The homo glycopolymer of mannose, P1, bound with a KD of
4.96 × 10-10 M. However, no signiﬁcant galactose glycopolymer P5
binding was observed, highlighting the speciﬁcity of the binding site
for terminal mannose residues with equatorial C3 and C4 hydroxyl
groups. The glyco copolymers P2-P4 were tested in the same system.
As expected, it was shown that increased galactose density correlated
negatively with binding afﬁnity to DC-SIGN. The calculated apparent
KD values for the full glycopolymer series are indicated in Table 1.
As a comparison, the calculated KD value for gp120 was found to be
4.24 × 10-12 M. This low KD value highlights the strong binding
provided by the exquisite presentation of branched carbohydrates in
gp120, which contributes toward the high afﬁnity of HIV-1 for human
dendritic cells. Furthermore, binding studies using DC-SIGN trans-
fected cells yield apparent KD values within the same order of
magnitude.
35 Therefore, it can be concluded that the SPR assay offers
a good reﬂection of binding events at the cell surface.
A therapeutic role for mannose-containing glycopolymers would
lie in their potential to interrupt viral adhesion to host receptors, a
process referred to as anti-adhesion therapy. We therefore estab-
lished a competition assay within the SPR system to examine
whether the glycopolymers could inhibit DC-SIGN interactions with
HIV gp120, Figure 1b. Recombinant HIV gp120 was immobilized
on a sensor chip surface, and soluble DC-SIGN at a ﬁxed
concentration of 2 nM was ﬂowed over the surface in the presence
of the glycopolymers at a range of concentrations. The concentration
of polymer required to prevent 50% of the DC-SIGN from binding
to the gp120 surface (IC50) was determined. Figure 3 shows
representative SPR sensorgrams used to calculate the IC50 value;
further details are given in the Supporting Information. An increase
in the mannose content of the polymers from 25 to 100% reduces
the IC50 value from 1453 to 37 nM, highlighting the enhanced
avidity due to multivalent presentation of the binding epitopes, i.e.,
the cluster glycoside effect, Figure 4. When expressed as the relative
inhibition per mannose residue, P1 (100% mannose) has almost
10 times the avidity compared to P4 (25% mannose). These values
are in good agreement with the calculated values of KD, Table 1.
P5 showed only a weak inhibitory effect, and a value of IC50 could
not be calculated using the concentration range tested.
Figure 3. Competition experiments on gp120 functionalized surface between
DC-SIGN and homo Man-polymer P1 (left) or homo Gal-polymer P5 (right) at a
concentration range of 0-400 nM for the glycopolymers and 4 nM DC-SIGN.
Figure 4. IC50 and relative afﬁnities per mannose (cylinders) of the
glycopolymers in solution obtained from SPR competitive binding measure-
ments. Purple and orange represents the relative ratio of mannose and galactose
in the copolymer, respectively.
Figure 1. Experimental design. (a) DC-SIGN functionalized surface for
evaluating glycopolymers binding afﬁnity. (b) gp120 functionalized surface
for competitive binding studies. (Bottom) Schematic structures of DC-SIGN
and gp120 and the glycopolymer chemical structure.
Figure 2. SPR sensorgrams showing the binding of gp120 (left) and P1
(right) onto DC-SIGN functionalized surfaces. The concentration ranges
for P1 and gp120 were 16.9-270 and 0.172-2.6 nM, respectively.
Table 1. Binding Data of gp120 and Glycopolymers Obtained from
SPR Measurements
DC-SIGN binding
code Man (%) Gal (%) kon (M-1s-1)k off (s-1) KD (nM)
gp120 na na 8.89 × 106 3.77 × 10-5 0.004
P1 100 - 4.99 × 105 2.48 × 10-4 0.496
P2 75 25 2.98 × 105 1.79 × 10-4 0.602
P3 50 50 2.42 × 105 2.01 × 10-4 0.832
P4 25 75 2.37 × 105 4.75 × 10-4 2.01
P5 - 100 na na na
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COMMUNICATIONSIt is clear that exploitation of the carbohydrate-binding of human
cells by pathogens is a signiﬁcant mechanistic feature of several
devastating infectious diseases. In addition to supporting HIV
adhesion and infection, DC-SIGN is also strongly implicated in
the uptake and chronic infectivity of other lethal viruses, including
hepatitis C virus and Ebola virus, pathogens that collectively cause
disease in millions of human beings.
35,36 Thus, the power to unravel
these adhesion mechanisms, and positively interfere with them,
carries the potential to provide substantial global healthcare beneﬁt.
Herein, we have shown that a relatively simple glycopolymer can
effectively prevent the interactions between a human dendritic cell-
associated lectin (DC-SIGN) and the viral envelope glycoprotein
gp120. This approach may give rise to novel insights into the
mechanisms of HIV infection and provide potentially important
components to new therapeutics, notably novel topical barrier
therapeutics.
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